Prof Jonathan Benger is currently deputy CEO of the health technology assessment (HTA) agency. Prof Jonathan Benger will take over from Dr Samantha Roberts as chief executive of UK reimbursement ...

Alzheimer's Society welcomes the decision and says the Government must be ambitious about preparing for new treatments. Michelle Dyson CB, Chief Executive Officer at Alzheimer’s Society, said: 'We ...

The president of Les Républicains, Bruno Retailleau, in Paris, on March 8, 2026. XAVIER FRANCOLON/SIPA Bruno Retailleau chose a "neither-nor" approach for the second round of Nice's mayoral election, ...

Nice Interactive Solutions India Private Limited has leased around 1.63 lakh sq ft of office space in Pune’s Hinjewadi area for a total rent of over ₹44 crore, according to property registration ...

Nice delivered Q4 results that beat expectations, with sales and earnings per share rising 9% and 7%. However, its AI-related sales growth of 66% stole the show, pushing the stock higher. Trading at ...

Black Creek Investment Management sold 271,072 shares of NICE; the estimated trade value was $32.75 million based on quarterly average pricing. Meanwhile, the quarter-end position value decreased by ...

After more than five months in US President Donald Trump’s tariff prison, India is finally free. The punitive 50% duty that was threatening its manufacturing industries will fall to 18%, a tad better ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

ATLANTA--(BUSINESS WIRE)--FLOR®, the high-end area rug brand for homes, offices, and every space in between, today introduces its Winter Collection, which features new carpet tile styles that explore ...

Whether or not INEOS make a healthy return on their investment in fallen Premier League giants Manchester United remains to be seen, but at the other club owned by Sir Jim Ratcliffe’s company, OGC ...

This change, from April 2026, is designed to improve the operating environment for pharmaceutical companies in the UK to maximise the government’s commitment to unlock innovation and support the ...